Loading clinical trials...

Serotonin 1A Agonists and Cognition in Schizophrenia | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Serotonin 1A Agonists and Cognition in Schizophrenia

NCT00178971•Northwestern University

Summary

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.

Detailed Description

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects must meet all of the following criteria to be eligible for participation in the current research study.
•1. Subjects will be males and females between 18-65 years of age;
•2. Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
•3. The subjects or their legal guardian must sign the informed consent;
•4. Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months

Exclusion Criteria

•1. Subjects who are pregnant or lactating
•2. Subjects who have brain damage and/or neurological disorders
•3. Subjects who have current substance dependence
•4. Subjects unable to provide informed consent

Locations (1)

Psychiatric Hospital at Vanderbilt

Nashville, Tennessee, United States

Key Dates

Start Date

January 1, 2003

Primary Completion Date

October 1, 2004

Completion Date

October 1, 2004

Last Updated

June 7, 2017

Enrollment

ACTUAL participants

Conditions

SchizophreniaSchizoaffective Disorder

Interventions

adjunctive treatment with buspirone

DRUG

placebo

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 7, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Serotonin 1A Agonists and Cognition in Schizophrenia

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia